These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15031804)

  • 1. Role of pertactin in pertussis vaccines: the jury is still out.
    Desauziers E; Danve B; Decker MD; Veitch K
    J Infect Dis; 2004 Apr; 189(7):1332-3; author reply 1333-5. PubMed ID: 15031804
    [No Abstract]   [Full Text] [Related]  

  • 2. Crucial role of antibodies to pertactin in Bordetella pertussis immunity.
    Hellwig SM; Rodriguez ME; Berbers GA; van de Winkel JG; Mooi FR
    J Infect Dis; 2003 Sep; 188(5):738-42. PubMed ID: 12934190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis.
    Trollfors B; Zackrisson G; Taranger J; Lagergård T
    J Pediatr; 1992 Jun; 120(6):924-6. PubMed ID: 1593352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Components of acellular pertussis vaccines.
    Preston NW; Matthews RC
    Lancet; 1996 Mar; 347(9003):764. PubMed ID: 8602023
    [No Abstract]   [Full Text] [Related]  

  • 6. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
    Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
    Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.
    Hijnen M; He Q; Schepp R; Van Gageldonk P; Mertsola J; Mooi FR; Berbers GA
    Scand J Infect Dis; 2008; 40(2):94-104. PubMed ID: 17926203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.
    Hijnen M; Mooi FR; van Gageldonk PG; Hoogerhout P; King AJ; Berbers GA
    Infect Immun; 2004 Jul; 72(7):3716-23. PubMed ID: 15213111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.
    Grimprel E; Bégué P; Anjak I; Njamkepo E; François P; Guiso N
    Clin Diagn Lab Immunol; 1996 Jan; 3(1):93-7. PubMed ID: 8770511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of whooping cough bacterium may reduce vaccine effectiveness.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1430. PubMed ID: 25396233
    [No Abstract]   [Full Text] [Related]  

  • 11. Pertussis vaccine: a critique.
    Robbins JB; Schneerson R; Keith JM; Miller MA; Kubler-Kielb J; Trollfors B
    Pediatr Infect Dis J; 2009 Mar; 28(3):237-41. PubMed ID: 19165133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.
    Xu Y; Wang Y; Tan Y; Zhang H; Wu L; Wang L; Hou Q; Zhang S
    BMC Microbiol; 2009 Dec; 9():274. PubMed ID: 20040101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.
    Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R
    Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
    Hegerle N; Dore G; Guiso N
    Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.
    Lam C; Octavia S; Ricafort L; Sintchenko V; Gilbert GL; Wood N; McIntyre P; Marshall H; Guiso N; Keil AD; Lawrence A; Robson J; Hogg G; Lan R
    Emerg Infect Dis; 2014 Apr; 20(4):626-33. PubMed ID: 24655754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013-2017.
    Xu Z; Octavia S; Luu LDW; Payne M; Timms V; Tay CY; Keil AD; Sintchenko V; Guiso N; Lan R
    Emerg Infect Dis; 2019 Jun; 25(6):1196-1199. PubMed ID: 31107218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whooping cough surveillance in France in pediatric private practice in 2006-2015.
    Guiso N; Levy C; Romain O; Guillot S; Werner A; Rondeau MC; Béchet S; Cohen R
    Vaccine; 2017 Oct; 35(45):6083-6088. PubMed ID: 28974408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of recombinant and native pertactin of Bordetella pertussis.
    Xu Y; Zhang S; Bolgiano B; Tan Y; Asokanathan C; Zhang H; Xing D; Wang J
    Vaccine; 2011 Feb; 29(10):1974-80. PubMed ID: 21216309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.